Updated Feb. 8, 2012 at 7:38 a.m.
Drug research
Image 1 of 3 · Next Image…
Research Triangle Park, N.C. — Analysis: While AstraZeneca cuts, GSK is putting itself in a position to discover, develop and position for approval of a wider array of potential drug candidates. It's a strategy that should pay off in the best of times, and the worst of times....Copyright 2013 MedCity. All rights reserved.
Tale of two drug giants: GSK's pipeline full, AstraZeneca's dwindles
Post a comment
Print this blog postE-mail blog post
Share
Drug research
Image 1 of 3 · Next Image…
Research Triangle Park, N.C. — Analysis: While AstraZeneca cuts, GSK is putting itself in a position to discover, develop and position for approval of a wider array of potential drug candidates. It's a strategy that should pay off in the best of times, and the worst of times....Copyright 2013 MedCity. All rights reserved.
Please log in or register to view WRALTechWire Insider content
To access this premium content and other benefits, become a WRAL TechWire Insider. Daily, monthly, and annual memberships available.
Please Log In to add a comment.
Best of TechWire Insider
OUR INSIDERS
WRAL TechWire Editor
The Skinny
IBM layoff update: North American cuts climb; mum is word down under- At last! Sprint 4G service formally launches in Triangle
- Big Blue's layoff total climbs in RTP; North America total surges past 2,800
- Big Blue layoff count nears 2,800 in North America alone
- NC's high-tech job picture improves in May, but ...
- IBM layoff count hits nearly 2,300 across 31 work groups
- NC IDEA: Startup deal flow 'better than it has ever been'
- IBM's job cuts are global, nearing 4,000; most are in U.S.
- CEO fears for future of NC Biofuels Center due to budget cuts
- Workers 50+ take biggest hit among 14% reduction in IBM marketing group